Evaluation of gonadotropin-replacement therapy in male patients with hypogonadotropic hypogonadism.


Journal

Asian journal of andrology
ISSN: 1745-7262
Titre abrégé: Asian J Androl
Pays: China
ID NLM: 100942132

Informations de publication

Date de publication:
Historique:
pubmed: 8 5 2019
medline: 18 8 2020
entrez: 8 5 2019
Statut: ppublish

Résumé

Hypogonadotropic hypogonadism (HH) is a rare disease in which medical treatment has a high success rate to achieve fertility. This study aimed to analyze the efficacy of hormone replacement therapy and determine predictive factors for successful spermatogenesis and spontaneous pregnancy in patients with idiopathic HH. A total of 112 patients with low testosterone (T), luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and normal prolactin levels were diagnosed with HH and administered LH and FSH analogs as hormone replacement therapy. During treatment, 96 (85.7%) patients had sperm present in ejaculate samples. Among these patients, 72 were married and wanted a child. Of these 72 patients, 48 (66.7%) of couples had pregnancies from natural conception. After initiation of treatment, the mean time for the appearance of sperm in semen was 9.48 months. There were no significant differences between baseline FSH, T, and LH levels; however, older age, larger testicular size, and low rate of undescended testes were favorable factors for successful spermatogenesis. Larger testicular size and older age were also the main predictive factors for natural conception. We found that patients with undescended testes had a younger age, smaller testes, and lower T levels compared with patients exhibiting descended testes. The rate of sperm found in the ejaculate was not significantly decreased in patients with undescended compared with descended testis (73.7% vs 87.6%, P = 0.261). The medical approach for males with HH and azoospermia provides a successful treatment modality in regard to successful spermatogenesis and achievement of pregnancy.

Identifiants

pubmed: 31062720
pii: 257693
doi: 10.4103/aja.aja_6_19
pmc: PMC6859661
doi:

Substances chimiques

Chorionic Gonadotropin 0
Gonadotropins 0
Luteinizing Hormone 9002-67-9
Follicle Stimulating Hormone 9002-68-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

623-627

Déclaration de conflit d'intérêts

None

Références

Urology. 2007 Jan;69(1):158-62
pubmed: 17270640
Eur J Endocrinol. 2016 Jun;174(6):R267-74
pubmed: 26792935
Horm Res Paediatr. 2016;86(2):106-116
pubmed: 27487097
J Clin Endocrinol Metab. 1987 Feb;64(2):283-91
pubmed: 3098771
Eur Urol. 2005 Nov;48(5):703-11
pubmed: 16005562
Front Endocrinol (Lausanne). 2014 Jul 09;5:109
pubmed: 25071724
Reproduction. 2010 Jan;139(1):177-84
pubmed: 19846485
J Urol. 2005 Jun;173(6):2072-5
pubmed: 15879837
Eur J Endocrinol. 1998 Sep;139(3):298-303
pubmed: 9758439
J Clin Endocrinol Metab. 2002 Sep;87(9):4128-36
pubmed: 12213860
J Clin Endocrinol Metab. 2013 Nov;98(11):E1790-5
pubmed: 24037890
Endocr Dev. 2016;30:60-78
pubmed: 26683738
Fertil Steril. 2007 Dec;88(6):1697-9
pubmed: 17276437
Int J Androl. 1994 Oct;17(5):241-7
pubmed: 7698849
Mol Cell Endocrinol. 2000 Mar 30;161(1-2):73-88
pubmed: 10773395
J Clin Endocrinol Metab. 1988 Jun;66(6):1144-51
pubmed: 3372679
Fertil Steril. 2009 Sep;92(3):979-90
pubmed: 18930190
Fertil Steril. 2002 Feb;77(2):270-3
pubmed: 11821082
J Clin Endocrinol Metab. 1985 Oct;61(4):746-52
pubmed: 3928676
J Clin Endocrinol Metab. 2013 May;98(5):1781-8
pubmed: 23650335
Andrology. 2014 Nov;2(6):794-808
pubmed: 25271205
Pituitary. 2010 Jun;13(2):105-10
pubmed: 19838805
Clin Endocrinol (Oxf). 2010 Jun;72(6):731-7
pubmed: 19912242
J Clin Endocrinol Metab. 2009 Mar;94(3):801-8
pubmed: 19066302
Nat Rev Endocrinol. 2015 Sep;11(9):547-64
pubmed: 26194704
Fertil Steril. 2009 Aug;92(2):594-604
pubmed: 18930225
Medicine (Baltimore). 2016 Mar;95(9):e2867
pubmed: 26945370
Semin Cell Dev Biol. 2014 May;29:55-65
pubmed: 24598767
Fertil Steril. 1998 Aug;70(2):256-62
pubmed: 9696217
Hum Reprod. 2002 Mar;17(3):625-33
pubmed: 11870114
Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):91-103
pubmed: 25617175

Auteurs

Mazhar Ortac (M)

Haseki Training and Research Hospital, Department of Urology, Istanbul 34096, Turkey.

Muhammed Hidir (M)

Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34104, Turkey.

Emre Salabas (E)

Department of Urology, Biruni University Hospital, Istanbul 34295, Turkey.

Abubekir Boyuk (A)

Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34104, Turkey.

Caner Bese (C)

Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34104, Turkey.

Yasar Pazir (Y)

Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34104, Turkey.

Ates Kadioglu (A)

Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34104, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH